From: Albumin-based drug delivery: harnessing nature to cure disease
Attachment | Name | Disease | Drug type | Clinical status | Company | Ref |
---|---|---|---|---|---|---|
Non-covalent/reversible association | Levemir® | Diabetes type 1 and 2 | Insulin detemir | Marketed | Novo Nordisk | |
Victoza® | Diabetes type 2 | GLP-1 | Marketed | Novo Nordisk | [123] | |
Ozoralizumab | Rheumatoid arthritis | Antibody derivative | Phase II completed | Ablynx | [90] | |
Covalent | MTX-HSA | Cancer and autoimmune diseases | Methotrexate | Phase II | Access Pharmaceuticals Inc. | |
Aldoxorubicin | Cancer | Doxorubicin | Phase I completed | CytRx, Inc. | ||
 | CJC-1134 | Diabetes type 2 | Exendin-4 | Phase II | ConjuChem | |
Genetic fusion | Eperzan/Tanzeum | Diabetes type 2 | GLP-1 | Marketed | Glaxo Smith Kline | |
N/A | Hemophilia | FVIIa | Phase I completed | CSL Behring GmbH | ||
N/A | Hemophilia B | rIX-FP | Phase III completed | CSL Behring GmbH | [139] | |
Albuferon®/Zalbin/Jouleferon | Hepatitis C | INFalpha-2b | Phase III completed, Development ceased | Human Genome Sciences in collaboration with Novartis | ||
Micro-/Nanoparticle | Abraxane® | Cancer | Paclitaxel | Marketed | Celgene | [141] |
ABI-008 | Cancer | Docetaxel | Phase I/II | Celgene | [95] | |
ABI-009 | Cancer | Rapamycin | Phase I/II | Celgene | [96] | |
ABI-010 | Cancer | HSP90 Inhibitor | Withdrawn before enrollment | Celgene | [97] | |
99mTc-Albures | Diagnostic purpose | Technetium-99 | Marketed | GE Healthcare | Â | |
99mTc-Nanocoll | Diagnostic purpose | Technetium-99 | Marketed | GE Healthcare | Â |